Stock Analysis on Net

Biogen Inc. (NASDAQ:BIIB)

$22.49

This company has been moved to the archive! The financial data has not been updated since October 25, 2022.

Economic Value Added (EVA)

Microsoft Excel

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Economic Profit

Biogen Inc., economic profit calculation

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
Net operating profit after taxes (NOPAT)1
Cost of capital2
Invested capital3
 
Economic profit4

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

1 NOPAT. See details »

2 Cost of capital. See details »

3 Invested capital. See details »

4 2021 Calculation
Economic profit = NOPAT – Cost of capital × Invested capital
= × =


The period between 2017 and 2021 demonstrates a fluctuating pattern in financial performance as measured by economic profit. Net operating profit after taxes (NOPAT) initially increased significantly, followed by a substantial decline. Simultaneously, the cost of capital decreased over the period, while invested capital exhibited an initial rise, then a decrease, and a subsequent increase.

NOPAT Trend
NOPAT experienced considerable growth from 2017 to 2019, increasing from US$2,890,089 thousand to US$6,023,385 thousand. However, a marked decrease occurred in 2020, falling to US$4,370,868 thousand, and continued downward in 2021 to US$1,501,467 thousand. This suggests a weakening in operational profitability towards the end of the analyzed period.
Cost of Capital Trend
The cost of capital showed a slight increase from 9.40% in 2017 to 9.43% in 2018, then decreased steadily to 8.56% in 2021. This indicates a decreasing cost of financing operations over time, potentially due to changes in market conditions or the company’s financial risk profile.
Invested Capital Trend
Invested capital increased from US$12,476,129 thousand in 2017 to US$14,142,400 thousand in 2019. A decrease was observed in 2020 to US$12,625,400 thousand, followed by an increase to US$13,824,500 thousand in 2021. These fluctuations may reflect changes in capital expenditure, asset sales, or working capital management.
Economic Profit Trend
Economic profit mirrored the trend in NOPAT, rising from US$1,716,758 thousand in 2017 to a peak of US$4,706,130 thousand in 2019. Subsequently, economic profit declined to US$3,265,542 thousand in 2020 and further to US$317,865 thousand in 2021. This indicates that while the company generated profits, the returns exceeded the cost of capital to a lesser extent in the later years of the period.

The substantial decline in both NOPAT and economic profit from 2019 to 2021 warrants further investigation. While the decreasing cost of capital partially offset the impact of lower NOPAT, the overall trend suggests a diminishing ability to generate returns exceeding the cost of capital. The fluctuations in invested capital also contribute to the overall complexity of the financial performance during this period.


Net Operating Profit after Taxes (NOPAT)

Biogen Inc., NOPAT calculation

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
Net income attributable to Biogen Inc.
Deferred income tax expense (benefit)1
Increase (decrease) in reserves for allowances2
Increase (decrease) in restructuring reserve3
Increase (decrease) in equity equivalents4
Interest expense
Interest expense, operating lease liability5
Adjusted interest expense
Tax benefit of interest expense6
Adjusted interest expense, after taxes7
(Gain) loss on marketable securities
Interest income
Investment income, before taxes
Tax expense (benefit) of investment income8
Investment income, after taxes9
Net income (loss) attributable to noncontrolling interest
Net operating profit after taxes (NOPAT)

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

1 Elimination of deferred tax expense. See details »

2 Addition of increase (decrease) in reserves for allowances.

3 Addition of increase (decrease) in restructuring reserve.

4 Addition of increase (decrease) in equity equivalents to net income attributable to Biogen Inc..

5 2021 Calculation
Interest expense on capitalized operating leases = Operating lease liability × Discount rate
= × =

6 2021 Calculation
Tax benefit of interest expense = Adjusted interest expense × Statutory income tax rate
= × 21.00% =

7 Addition of after taxes interest expense to net income attributable to Biogen Inc..

8 2021 Calculation
Tax expense (benefit) of investment income = Investment income, before tax × Statutory income tax rate
= × 21.00% =

9 Elimination of after taxes investment income.


Net Income Attributable to Biogen Inc.
The net income exhibited a rising trend from 2017 to 2019, increasing from approximately 2.54 billion to nearly 5.89 billion US dollars. However, a decline was observed starting in 2020, with net income falling to about 4.00 billion and further decreasing sharply to approximately 1.56 billion US dollars in 2021. This indicates a significant reduction in profitability during the latter years of the period.
Net Operating Profit After Taxes (NOPAT)
The NOPAT followed a similar trajectory to net income, showing an increase from about 2.89 billion US dollars in 2017 to a peak of approximately 6.02 billion US dollars in 2019. Subsequently, a decline occurred with NOPAT decreasing to roughly 4.37 billion in 2020 and then sharply dropping to around 1.50 billion US dollars in 2021. This pattern signifies a reduction in operating efficiency and effectiveness in generating profit after taxes over the last two years.
Overall Observations
Both net income and NOPAT demonstrated growth during the initial three years, suggesting improved financial performance and operational results. The peak in 2019 represents the highest point in profitability within the analyzed period. The subsequent decline in 2020 and more pronounced drop in 2021 highlight challenges or adverse developments affecting profitability and operational outcomes. The data suggests the company experienced a notable downturn in earning capacity and operating profit in the final years.

Cash Operating Taxes

Biogen Inc., cash operating taxes calculation

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
Income tax expense
Less: Deferred income tax expense (benefit)
Add: Tax savings from interest expense
Less: Tax imposed on investment income
Cash operating taxes

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).


Income Tax Expense
The income tax expense demonstrates a consistent downward trend from 2017 to 2021. Starting at 2,458,700 thousand US dollars in 2017, the expense decreased significantly each year to reach 52,500 thousand US dollars in 2021. The reduction is particularly notable in 2021, where the expense dropped sharply compared to previous years.
Cash Operating Taxes
Cash operating taxes also show a general decline over the analyzed period. Beginning at 2,441,355 thousand US dollars in 2017, these taxes declined steadily year over year, falling to 533,599 thousand US dollars in 2021. The reduction is gradual until 2020, followed by a less steep but still notable decrease in 2021.
Comparative Analysis
Both income tax expense and cash operating taxes have followed a downward trajectory, reflecting a possible strategic or operational improvement affecting taxable income or tax planning. The income tax expense decreased more sharply between 2020 and 2021 compared to prior years, whereas cash operating taxes reduced more steadily across the entire timeframe.

Invested Capital

Biogen Inc., invested capital calculation (financing approach)

US$ in thousands

Microsoft Excel
Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
Current portion of notes payable
Notes payable, excluding current portion
Operating lease liability1
Total reported debt & leases
Total Biogen Inc. shareholders’ equity
Net deferred tax (assets) liabilities2
Reserves for allowances3
Restructuring reserve4
Equity equivalents5
Accumulated other comprehensive (income) loss, net of tax6
Noncontrolling interests
Adjusted total Biogen Inc. shareholders’ equity
Construction in progress7
Marketable securities8
Invested capital

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

1 Addition of capitalized operating leases.

2 Elimination of deferred taxes from assets and liabilities. See details »

3 Addition of allowance for doubtful accounts receivable.

4 Addition of restructuring reserve.

5 Addition of equity equivalents to total Biogen Inc. shareholders’ equity.

6 Removal of accumulated other comprehensive income.

7 Subtraction of construction in progress.

8 Subtraction of marketable securities.


Total Reported Debt & Leases
The total reported debt and leases remained relatively stable from 2017 to 2019, with a slight decrease each year from approximately 6.45 billion US dollars to around 6.44 billion US dollars. However, there was a significant increase in 2020, rising to approximately 7.91 billion US dollars. In 2021, the debt slightly decreased to about 7.69 billion US dollars, indicating a reduction after the peak the previous year.
Total Biogen Inc. Shareholders’ Equity
Shareholders' equity showed a consistent upward trend from 2017 to 2019, growing from approximately 12.61 billion US dollars to 13.34 billion US dollars. In 2020, there was a notable decline to about 10.70 billion US dollars. This followed by a modest recovery in 2021, with equity increasing to approximately 10.90 billion US dollars, yet still below the peak levels observed in 2019.
Invested Capital
Invested capital experienced steady growth from 2017 through 2019, rising from approximately 12.48 billion US dollars to 14.14 billion US dollars. In 2020, invested capital dropped to about 12.63 billion US dollars but rebounded in 2021 to 13.82 billion US dollars. This pattern suggests some disruptions or adjustments during 2020, followed by partial recovery the following year.

Cost of Capital

Biogen Inc., cost of capital calculations

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Notes payable, including current portion3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2021-12-31).

1 US$ in thousands

2 Equity. See details »

3 Notes payable, including current portion. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Notes payable, including current portion3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2020-12-31).

1 US$ in thousands

2 Equity. See details »

3 Notes payable, including current portion. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Notes payable, including current portion3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2019-12-31).

1 US$ in thousands

2 Equity. See details »

3 Notes payable, including current portion. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Notes payable, including current portion3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2018-12-31).

1 US$ in thousands

2 Equity. See details »

3 Notes payable, including current portion. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Notes payable, including current portion3 ÷ = × × (1 – 35.00%) =
Operating lease liability4 ÷ = × × (1 – 35.00%) =
Total:

Based on: 10-K (reporting date: 2017-12-31).

1 US$ in thousands

2 Equity. See details »

3 Notes payable, including current portion. See details »

4 Operating lease liability. See details »


Economic Spread Ratio

Biogen Inc., economic spread ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
Selected Financial Data (US$ in thousands)
Economic profit1
Invested capital2
Performance Ratio
Economic spread ratio3
Benchmarks
Economic Spread Ratio, Competitors4
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

1 Economic profit. See details »

2 Invested capital. See details »

3 2021 Calculation
Economic spread ratio = 100 × Economic profit ÷ Invested capital
= 100 × ÷ =

4 Click competitor name to see calculations.


The economic spread ratio demonstrates significant fluctuation over the observed five-year period. Initially, the ratio exhibits a strong upward trend, followed by a substantial decline.

Economic Spread Ratio Trend
The economic spread ratio increased from 13.76% in 2017 to a peak of 33.28% in 2019, indicating a growing ability to generate returns exceeding the cost of capital. This represents a period of improving profitability relative to invested capital. However, a marked decrease is then observed, with the ratio falling to 25.86% in 2020 and plummeting to 2.30% in 2021. This suggests a significant erosion in the company’s ability to generate economic profit relative to the capital employed.

The economic spread ratio’s decline in the latter years coincides with fluctuations in economic profit. While invested capital remained relatively stable, the substantial reduction in economic profit in 2021 directly drove the dramatic decrease in the economic spread ratio.

Relationship to Economic Profit
Economic profit increased consistently from 2017 to 2019, mirroring the rise in the economic spread ratio. The subsequent decline in economic profit from 2019 to 2021 directly correlates with the decreasing economic spread ratio. This indicates that the economic spread ratio is highly sensitive to changes in economic profit.

The observed trend suggests a weakening of the company’s competitive advantage or an increase in the cost of capital, or a combination of both, particularly in the most recent year. Further investigation into the drivers of the decline in economic profit is warranted.

Invested Capital Stability
Invested capital experienced moderate growth between 2017 and 2019, increasing from US$12,476,129 thousand to US$14,142,400 thousand. A decrease was noted in 2020, followed by a rebound in 2021 to US$13,824,500 thousand. The relative stability of invested capital suggests that changes in the economic spread ratio are primarily driven by fluctuations in economic profit, rather than significant shifts in the capital base.

Economic Profit Margin

Biogen Inc., economic profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
Selected Financial Data (US$ in thousands)
Economic profit1
Revenue
Performance Ratio
Economic profit margin2
Benchmarks
Economic Profit Margin, Competitors3
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

1 Economic profit. See details »

2 2021 Calculation
Economic profit margin = 100 × Economic profit ÷ Revenue
= 100 × ÷ =

3 Click competitor name to see calculations.


The economic profit margin exhibited a fluctuating trend over the observed five-year period. Initially, the margin demonstrated substantial growth, followed by a significant decline in the most recent year.

Economic Profit Margin Trend
In 2017, the economic profit margin stood at 13.99%. This figure increased considerably to 25.43% in 2018, indicating improved profitability relative to economic costs. The margin continued its upward trajectory, reaching a peak of 32.73% in 2019. A subsequent decrease was observed in 2020, with the margin falling to 24.29%. The most pronounced change occurred in 2021, where the economic profit margin experienced a substantial decline to 2.89%, representing a significant reduction in economic profitability.

The economic profit margin’s performance appears closely linked to revenue fluctuations. While economic profit increased from 2017 to 2019, revenue also rose during this period. The decline in economic profit margin in 2020 coincided with a slight decrease in revenue. However, the dramatic drop in the margin in 2021 occurred alongside a more substantial decrease in revenue, suggesting that the reduction in revenue had a disproportionately negative impact on economic profitability.

Revenue Correlation
Revenue decreased from US$13,444.6 million in 2020 to US$10,981.7 million in 2021, a reduction of approximately 18.3%. This substantial revenue decline appears to be a primary driver of the significant decrease in the economic profit margin observed in 2021.

The observed trend suggests a sensitivity of economic profitability to revenue levels. Further investigation into the factors contributing to the revenue decline in 2021 would be beneficial to understand the underlying causes of the reduced economic profit margin.